<DOC>
	<DOCNO>NCT01541085</DOCNO>
	<brief_summary>The purpose study study kinetics ( study rate change ) immune recovery quality function store plasma blood sample treatment-naive ( previously treat antiretroviral drug ) patient advanced human immunodeficiency virus ( HIV ) infection start Darunavir/Ritonavir- Efavirenz-based highly active antiretroviral therapy ( HAART ) regimen .</brief_summary>
	<brief_title>An Immunologic Study Treatment-Naive HIV Patients Starting Darunavir/Ritonavir- Efavirenz-Based HAART</brief_title>
	<detailed_description>This ex-vivo study ( study take place outside organism record immune parameter store blood cell define population without intervention researcher ) evaluate kinetics ( study rate change ) immune recovery quality function store plasma blood sample treatment-naive ( previously treat antiretroviral drug ) patient advanced human immunodeficiency virus ( HIV ) infection start Darunavir/Ritonavir ( DRV/r ) - Efavirenz ( EFV ) -based highly active antiretroviral therapy ( HAART ) regimen . In previously store plasma blood sample , role DRV/r compare EFV reduce T-lymphocyte activation , DRV/r compare EFV recover T-lymphocyte immune phenotype peripheral blood thymic production , DRV/r compare EFV recover T-lymphocyte function ( functional immunity ) study . Blood sample analyze ( baseline ) 48 week initiate HAART . Each patient receive orally administer ( give mouth ) regimens either Darunavir/Ritonavir ( DRV/r ) + Tenofovir/Emtricitabina Efavirenz ( EFV ) + Tenofovir/Emtricitabina .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Documented human immunodeficiency ( HIV ) 1 infection At baseline plasma blood sampling , never receive antiretroviral therapy Attending Clinic Infectious Diseases University Milan San Paolo Hospital Asymptomatic ( demonstrate acquire immunodeficiency syndrome [ AIDS ] define symptom ) Baseline , Week 12 , Week 24 CD4 cell count &gt; 50 &lt; 250/mm3 Baseline Receiving treatment either Darunavir/Ritonavir + Tenofovir/Emtricitabina Efavirenz + Tenofovir/Emtricitabina highly active antiretroviral therapy ( HAART ) regimens Week 12 , Week 24 , Week 48 plasma blood sampling . Exclusion Criteria define protocol .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Human Immunodeficiency Virus ; HIV ; Highly Active Antiretroviral Therapy ; HAART ; Darunavir ; Ritonavir ; Efavirenz ; Kinetics ; Immunological Recovery</keyword>
</DOC>